{
    "name": "plazomicin",
    "comment": "Rx",
    "other_names": [
        "Zemdri"
    ],
    "classes": [
        "Aminoglycosides"
    ],
    "source": "https://reference.medscape.com/drug/zemdri-plazomicin-1000230",
    "pregnancy": {
        "common": [
            "Fetal harm may occur when administered to a pregnant woman",
            "There are no available data on this drug in pregnant women to inform a drug-associated risk of adverse developmental outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Published literature reports of streptomycin, an aminoglycoside, state that it can cause total, irreversible, bilateral congenital deafness in children whose mothers received streptomycin during pregnancy",
                    "No drug-related visceral or skeletal malformations were observed in pregnant rats and rabbits administered subcutaneous plazomicin during organogenesis at maternal exposures ~0.8-fold (rats) and 2.5-fold (rabbits) of the human AUC at the clinical dose of 15 mg/kg/day",
                    "Auditory function of offspring was not measured in animal studies",
                    "Advise pregnant women of the potential risk to a fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of plazomicin in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Plazomicin was detected in rat milk",
            "Consider developmental and health benefits of breastfeeding along with the mother's clinical need for plazomicin and any potential adverse effects on the breastfed infant from plazomicin or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Nephrotoxicity",
                    "description": [
                        "Nephrotoxicity reported; risk of nephrotoxicity is greater in patients with impaired renal function, elderly patients, and those receiving concomitant nephrotoxic medication",
                        "Assess CrCl in all patients prior to initiating therapy and daily during therapy",
                        "TDM is recommended for cUTI patients with CrCl <90 mL/min to avoid potentially toxic levels",
                        "See Dosage Modifications and Dosing Considerations"
                    ]
                },
                {
                    "type": "Ototoxicity",
                    "description": [
                        "Ototoxicity, manifested as hearing loss, tinnitus, and/or vertigo, has been reported",
                        "Symptoms of aminoglycoside-associated ototoxicity may be irreversible and may not become evident until after completion of therapy",
                        "Aminoglycoside-associated ototoxicity observed primarily in patients with a family history of hearing loss, patients with renal impairment, and patients receiving higher doses and/or longer durations of therapy than recommended",
                        "Benefit-risk of therapy should be considered in patients with symptoms of ototoxicity"
                    ]
                },
                {
                    "type": "Neuromuscular blockade",
                    "description": [
                        "Aminoglycosides have been associated with neuromuscular blockade",
                        "During therapy, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients (eg, patients with underlying neuromuscular disorders [including myasthenia gravis]) or in patients concomitantly receiving neuromuscular blocking agents"
                    ]
                },
                {
                    "type": "Pregnancy",
                    "description": [
                        "Aminoglycosides, including plazomicin, can cause fetal harm when administered to a pregnant woman",
                        "See Pregnancy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Patients with known hypersensitivity to any aminoglycoside"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Also see Black Box Warnings",
                "Nephrotoxicity reported; most serum creatinine increases were â‰¥1 mg/dL above baseline and reversible",
                "Aminoglycosides have been associated with exacerbation of muscle weakness in patients with underlying neuromuscular disorders, or delayed recovery of neuromuscular function in patients receiving concomitant neuromuscular blocking agents",
                "Fetal harm may occur when administered to a pregnant woman (see Pregnancy)",
                "Serious and occasionally fatal hypersensitivity (anaphylactic) reactions reported in patients receiving aminoglycoside antibacterial drugs; discontinue treatment if an allergic reaction occurs",
                "Prescribing a drug in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria"
            ],
            "specific": [
                {
                    "type": "Ototoxicity",
                    "description": [
                        "Cases of ototoxicity with antimicrobials#aminoglycosides have reported in patients with certain variants in mitochondrially encoded 12S rRNA gene (",
                        "MT-RNR1",
                        "), particularly the m.1555A>G variant; ototoxicity reported in some patients even when their aminoglycoside serum levels were within recommended range",
                        "In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than antimicrobials#aminoglycosides unless the increased risk of permanent hearing loss is outweighed by severity of infection and lack of safe and effective alternative therapies"
                    ]
                },
                {
                    "type": "Clostridium difficile-associated diarrhea",
                    "description": [
                        "Clostridium difficile-associated diarrhea (CDAD) reported for nearly all systemic antibacterial drugs and may range in severity from mild diarrhea to fatal colitis",
                        "Treatment with antibacterial drugs alters the normal flora of the colon and may permit overgrowth of C difficile; careful medical history is necessary",
                        "If CDAD is suspected or confirmed, antibacterial drugs not directed against C difficile may need to be discontinued"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Decreased renal function",
            "percent": "3.6"
        },
        {
            "name": "Diarrhea",
            "percent": "2.3"
        },
        {
            "name": "Hypertension",
            "percent": "2.3"
        },
        {
            "name": "Treatment",
            "percent": "2.2"
        },
        {
            "name": "associated ototoxicity",
            "percent": "1.3"
        },
        {
            "name": "Headache",
            "percent": "1.3"
        },
        {
            "name": "Nausea",
            "percent": "1.3"
        },
        {
            "name": "Vomiting",
            "percent": "1"
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "gastritis",
            "percent": null
        },
        {
            "name": "Laboratory investigations",
            "percent": null
        },
        {
            "name": "Alanine aminotransferase increased",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Hematuria",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        }
    ]
}